Medication info
Hutmin Controlled-release Tablet (Metformin Hydrochloride)

Hutmin Controlled-release Tablet (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hubist Pharmaceutical Co., Ltd.
Appearance
White rectangular tablet
Packaging
30 tablets per bottle, 300 tablets per bottle
Approval status
Active

MFDS item code 201404986 · Approved 2014.10.28 · Insurance code 628800390

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum dose of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to this medication and determine the minimum effective dose. Blood hemoglobin A1c levels should be measured at approximately 3-month intervals. - The goal of treatment with this medication, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood hemoglobin A1c levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medication may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medication should be stopped immediately.

Ingredients

Manufacturer
Hubist Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for adult patients with type 2 diabetes whose blood sugar control is insufficient with diet and exercise alone, especially in those who are overweight. It can be used alone or in combination with other oral hypoglycemics or insulin as needed to effectively assist in blood sugar control.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum dose of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess the response to this medication and determine the minimum effective dose. Blood hemoglobin A1c levels should be measured at approximately 3-month intervals. - The goal of treatment with this medication, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood hemoglobin A1c levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medication may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medication should be stopped immediately.

Precautions

This medication helps lower blood sugar and is used in diabetes treatment. However, it may rarely cause a serious condition called lactic acidosis, so caution is needed. When used in conjunction with insulin or other diabetes medications, there is a risk of hypoglycemia, so care should be taken. This medication should not be used in patients with severely impaired kidney function, dehydration, severe infection, acute heart failure, or acute myocardial infarction. Additionally, it should be temporarily discontinued if iodinated contrast media used in certain tests are administered, and it should not be given to patients with liver dysfunction or during pregnancy if there are specific risks. Patients with irregular or insufficient food intake, those engaged in intense exercise, or those who may have interactions with other medications should use this drug cautiously. While taking this drug, gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.) are common, and vitamin B12 deficiency may occur, so regular blood tests are necessary. Rarely, skin rashes or allergic reactions may appear, and if any unusual symptoms occur, inform healthcare personnel. Regular monitoring of kidney function should be done to manage medication accumulation in the body, and if acute renal impairment is suspected, medication should be stopped immediately. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid it. During pregnancy, this medication may affect the fetus, so if planning to become pregnant or already pregnant, consult healthcare personnel, and caution is also needed if breastfeeding. The elderly may have decreased kidney function, so starting at a lower dose and regular monitoring are necessary. In case of overdose, while hypoglycemia is rare, there is a risk of lactic acidosis, requiring immediate medical attention. This medication should be swallowed whole and not chewed or crushed; the surface of the tablet may appear in the stool, which is normal. Finally, this medication may interact with other medications, so if currently taking any other medications, it is essential to inform healthcare personnel, and safety should be ensured through regular monitoring of blood glucose and kidney function.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste disturbances
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage will help preserve the medication's effectiveness.

Appearance and packaging

Appearance

White rectangular tablet

Package unit

30 tablets per bottle, 300 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.